Impact of Food and Drug Administration’s (FDA) final guidelines for risk based monitoring on...

Post on 03-Jul-2015

92 views 1 download

description

Current clinical research methods allocate monitoring resources (primarily Clinical Research Associates (CRAs)) uniformly among the clinical trial sites. Through the use of existing and new technologies, risk-based monitoring is expected to allocate resources across clinical trials based on their level of risk while maintaining data quality and patient safety. This is expected to reduce the trial monitoring cost by 10-20%. We have also attached the Webinar video where Beroe’s Senior Research Analyst, Ashwini, discusses the Impact of FDA’s final guidelines for risk-based monitoring (RBM) on clinical research and role of suppliers/partners in this space with: Dr. Rajesh Jain – Independent Clinical Research Consultant Moe Alsumidaie - President & Chief Scientific Officer, Annex Clinical To know more about Beroe's Procurement intelligence services for Healthcare, contact us here http://www.beroeinc.com/contact (or) Email: mktg@beroe-inc.com

transcript

2

• How to post a question?

• To log in again if the connection is lost, use the link in the confirmation mailer you would have received from gotowebinar@citrixonline.com

• In case you face any other issues write an email to puneet.ramaul@beroe-inc.com

Panel Members:

Dr. Rajesh Jain Clinical Research Consultant Independent Consultant Dialing in from:

India

Moe Alsumidaie President & Chief Scientific Officer Annex Clinical Dialing in from:

USA

Ashwini Tripathi Senior Research Analyst Beroe Inc. Dialing in from:

India

Host

Panel Members for the Webinar

Sharan Ramesh Engagement Manager Beroe Inc. Dialing in from:

India

Moderator

3

Release of Guidelines

15-25%

>35%

15-25%

CRAs will be enabled with analytical skills to identify problematic, missing

data before visiting a site.

41%

On site Monitoring

22%

Off site Monitoring

19%

Travel

13%

Administrative tasks

5%

Training

Lack of proven methodologies can impact the Engagement Model

between sponsor and the service providers

Source: CMR International Pharmaceutical R&D Factbook, 2012

Low High

1 5 2 3 4

Low High

1 5 2 3 4

Low High

1 5 2 3 4

Low High

1 5 2 3 4

Low High

1 5 2 3 4

Low High

1 5 2 3 4

Low High

1 5 2 3 4

Low High

1 5 2 3 4

Low High

1 5 2 3 4

Low High

1 5 2 3 4

Low High

1 5 2 3 4

Low High

1 5 2 3 4

Low High

1 5 2 3 4

Low High

1 5 2 3 4

Low High

1 5 2 3 4

Low High

1 5 2 3 4

Low High

1 5 2 3 4

TransCelerate

ADAMON

OPTIMON